The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis.

Mengyuan LiuFangfang FanYan ZhangJianping Li

Published in: European journal of clinical pharmacology (2020)

GATM polymorphism including rs9806699 G>A, rs1719247 C>T, and rs1346268 T>C may be protective factors of SIM. GATM rs9806699 G>A may only exert protective effect on mild SIM cases. Our meta-analysis indicates that GATM polymorphism may represent a pharmacogenomics biomarker for predicting incidence of SIM, which contributes to risk stratification and optimizing statin adherence.

Keyphrases

systematic review
cardiovascular disease
coronary artery disease
randomized controlled trial
type diabetes
emergency department
high glucose
late onset
adipose tissue
oxidative stress
low density lipoprotein
endothelial cells
adverse drug